Export

Dasatinib
Essential medicine status
General description
Dasatinib is a BCR-ABL tyrosine kinase inhibitor used in treatment protocols for various leukaemias.
INN
Dasatinib
Medicine type
Chemical agent
EML status history
First added in 2017 (TRS 1006) for Chronic myeloid leukaemia, NOS
Therapeutic equivalent for
Wikipedia
DrugBank
Recommendations
Section
Targeted therapies
  • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet